Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Maze Therapeutics has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Maze Therapeutics's investors include Andreessen Horowitz, General Catalyst, ARCH Venture Partners, Janus Henderson Investors, TCG Crossover.
Maze Therapeutics is headquartered in South San Francisco, United States.
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Maze Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Maze Therapeutics — Funding & Investors." VCBacked, April 22, 2026, https://www.vcbacked.co/company/maze-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Maze Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/maze-therapeutics
{{cite web |title=Maze Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/maze-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated